Earnings Call Intelligence Subscribe
Home › Call Sheets › MRK › Q1'26
Call sheet · Q1'26

Merck (MRK)

Q1'26 earnings call · held April 30, 2026 · compared with the Q4'25 call · management-credibility review
9/12
Disclosure score
1 high, 4 medium, 1 low flags
Financial quality
Bottom line
The sleeper story is KEYTRUDA's growth is inventory-driven, not demand-driven, with management warning of a $250M headwind in Q3 that reveals underlying weakness. While everyone focuses on the pipeline transformation, multiple new launches are missing targets - ENFLONSIA expects 'minimal Q2 sales' and OHTUVAYRE hit reimbursement headwinds. The binding constraint is execution risk: they have 20+ launches in motion but need massive acquisition writeoffs ($9B Cidara, $5.8B Terns coming) to fill pipeline gaps. As CFO Litchfield admitted, 'We are making investments to maximize the ongoing launch' - code for throwing money at struggling products. My view changes if Q3 KEYTRUDA shows the timing impact was truly temporary and new launches accelerate in H2 2026.

The 30-second version

  • KEYTRUDA growth is timing-driven, not organic - major Q3 payback coming
  • Portfolio transformation hitting execution risk - $9B Cidara writeoff signals M&A desperation
  • Cash flow quality deteriorating despite revenue growth

What changed this quarter

MetricQ4'25Q1'26Change
Total Revenue$16.4B (+5% YoY)$16.3B (+5% YoY)Flat sequentially, growth rate holding
KEYTRUDA Revenue$8.4B (+5% YoY)$8.0B (+8% YoY)+300 bps growth acceleration, but timing-distorted
GARDASIL Revenue$1.0B (-35% YoY)$1.1B (-22% YoY)+1300 bps improvement, still declining
WINREVAIR Revenue$467M$525M+12% sequential growth, demand holding
Animal Health RevenueNot disclosed Q4 growth+6% YoYSteady growth continuation
Gross Margin79.7%81.9%+220 bps improvement
Operating Expenses$6.8B$15.2B+124% explosion from Cidara charge
EPS (reported)$2.04-$1.28Loss due to Cidara writeoff
Tax Rate15.4%-43.5%Negative due to non-deductible charge
Revenue Guidance Midpoint$66.25B (midpoint of $65.5-67B)$66.4B (midpoint of $65.8-67B)+$150M guidance raise

Accountability tracked

7 new promises made4 narrative shifts flagged6 prior promises scored
Inside the full report
The complete write-up covers the full promise ledger with kept/missed calls, disclosure-quality scoring, the metrics-vanished check, verification items, and the questions to ask next quarter.
Read the full MRK Q1'26 report Subscribe
About Research ↗Call SheetsCredibility IndexMissed PromisesScreens13F BooksData & InstitutionalPrivacyTermsSubscribe
This is a free preview. The full write-up and promise ledger are published to subscribers on Substack.
Scores, kept-promise rates, and flags on this site reflect the author's opinion, applying a stated methodology to statements management made on public earnings calls. Informational and educational purposes only - not investment advice, a recommendation, or an offer to buy or sell any security. Sources believed reliable but not guaranteed; the author may hold positions in the securities discussed.

Follow what management promises next

Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.

Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.